REG - Venture Life Group - Appointment of Joint Broker

Venture LifeAnnouncement

13/07/2020 07:00

RNS Number : 7300S
  
Venture Life Group PLC
  
13 July 2020
  
 

13 July 2020


Venture Life Group plc
("Venture Life" the "Company" or the "Group")
Appointment of N+1 Singer as Joint Broker
 
Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces the appointment of N+1 Singer as Joint Broker effective immediately.  Cenkos Securities plc will continue as the Company's Nominated Adviser and Joint Broker. 
For further information, please contact:



Venture Life Group PLC


+44 (0) 1344 578004




Jerry Randall, Chief Executive Officer

Andrew Waters, Chief Financial Officer








 
Cenkos Securities plc (Nomad and Joint Broker)


 
+44 (0) 20 7397 8900




Stephen Keys / Mark Connelly / Cameron MacRitchie (Corporate Finance)








Russell Kerr / Michael Johnson (Sales)



 
N+1 Singer (Joint Broker)


 
+44 (0) 20 7496 3000




Shaun Dobson / Carlo Spingardi

























 
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands, these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 
Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies for consumer healthcare products, primarily medical devices.
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
APPDBLFFBDLEBBV